APOBEC3G and HIV-1 infection: However, the overall in vivo efficacy of this potential antiviral strategy remains unclear, as HIV-1 infection is known to reduce APOBEC3G in activated CD4+ T cells, thus potentially limiting the amount that can be trafficked into EVs [133].